Company Profile - Mesoblast Ltd

Introduction

Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in phase III trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia, and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.